Imricor Medical Systems has submitted its NorthStar Mapping System for FDA pediatric label expansion, aiming to accelerate adoption in over 250 US children’s hospitals and broaden its commercial footprint.
- NorthStar Mapping System submitted for FDA pediatric label expansion via Special 510(k) pathway
- Submission follows January 2026 FDA clearance for adult use
- Pediatric expansion targets over 250 US children’s hospitals showing inbound interest
- Clearance expected within the current quarter to support US commercialization
- Strategy aims to build installed base in pediatric centres ahead of adult hospital rollout
Regulatory Progress in Pediatric Cardiac Mapping
Imricor Medical Systems, Inc. (ASX:IMR) has taken a significant step in its US commercialisation strategy by submitting its NorthStar Mapping System to the US Food and Drug Administration (FDA) for pediatric label expansion. This submission, made via the FDA’s Special 510(k) pathway, follows the system’s clearance earlier this year for use in adult patients. The pediatric expansion aims to enable marketing and adoption of NorthStar in children’s hospitals across the United States.
Targeting the Pediatric Market
The company has received inbound interest from over 250 children’s hospitals in the US since the initial FDA clearance for adults. Imricor sees pediatric centres as a strategic early commercial channel for NorthStar, given these hospitals’ focus on reducing radiation exposure for young patients. NorthStar, designed for interventional cardiovascular magnetic resonance (iCMR) procedures, offers a navigation system that could improve workflows currently reliant on standard MRI interfaces.
Imricor’s Chair and CEO, Steve Wedan, highlighted the practical benefits of this submission, noting that establishing an installed base in pediatric hospitals could generate revenue, increase awareness of the technology, and position the company for broader rollout of its full electrophysiology (EP) platform in adult hospitals. He emphasised that Imricor is positioning itself as an interventional MR company, not solely focused on iCMR ablation.
Commercial and Regulatory Context
The pediatric label expansion, if cleared within the current quarter as expected, would allow Imricor to proactively market NorthStar for pediatric use, broadening its addressable market in the US. This regulatory milestone complements earlier steps in Imricor’s US market entry, including the recent filing of a Form 10 registration with the US Securities and Exchange Commission, which marked a transition to US reporting and supported ongoing FDA clearances and clinical trials. This filing was part of a broader effort to accelerate commercialisation of MRI-guided cardiac ablation technology in the US.
While the timing of FDA clearance is anticipated, it is not guaranteed, and actual uptake in pediatric hospitals will depend on multiple factors including clinical adoption and reimbursement pathways. Nonetheless, the submission reflects Imricor’s strategy to open multiple paths to market and build momentum ahead of a wider adult hospital rollout.
For further context on Imricor’s regulatory and commercial progress, see the company’s recent transition to US reporting and FDA clearance updates.
Bottom Line?
Imricor’s pediatric label expansion submission signals a strategic push to broaden NorthStar’s US market reach, but clearance timing and clinical adoption remain key uncertainties.
Questions in the middle?
- How quickly will pediatric hospitals adopt NorthStar following FDA clearance?
- What impact will pediatric market traction have on Imricor’s broader adult hospital rollout?
- How will reimbursement and clinical workflow integration influence NorthStar’s commercial success in pediatric settings?